Skip to content

Study · Systematic review · 2025

2 results

Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.

Tewari J, Qidwai KA, Tewari A, Kaur S, Tewari V, Maheshwari A

Expert review of clinical pharmacology16 Jan 2025Cited by 6 (Europe PMC)

PMID39817343 (opens in a new tab)DOI10.1080/17512433.2025.2450254 (opens in a new tab)PepBankPUB-39817343
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of four RCTs, retatrutide showed a dose-dependent relationship, with the 12 mg dose causing the largest reductions across all outcomes considered.

    In plain wordsIn a pooled analysis of four trials, higher retatrutide doses gave larger reductions, with 12 mg giving the most.

    Peptide
    Retatrutide
    Outcome
    DecreaseDose-dependent reductions across all outcomes considered
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    12 mg (maximum effect)As given in this study (human).

    Source sentences

    Summary
    After the initial search four RCTs were included in the analysis which compared the safety and efficacy of retatrutide versus placebo. Retatrutide showed a dose dependent relationship with the 12 mg dose causing the maximum reductions across all the outcomes considered.
    1 context sentence
    Summary · context
    A literature search was conducted in PubMed, Cochrane Central and Embase using appropriate search terms and randomized control trials (RCTs) were identified which reported the safety and efficacy of retatrutide.
  2. 02HumanSystematic reviewSafety outcome

    In a meta-analysis of four RCTs, the safety profile of retatrutide was comparable to the control group.

    In plain wordsIn a pooled analysis of four trials, the safety of retatrutide was found to be comparable to the control group.

    Peptide
    Retatrutide
    Outcome
    No significant changeOverall safety profile versus control
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The safety profile of retatrutide was found to be comparable to the control group.
    1 context sentence
    Summary · context
    After the initial search four RCTs were included in the analysis which compared the safety and efficacy of retatrutide versus placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.